Skip to main content Accessibility help
  • Online publication date: March 2018

3 - Multi-modality Imaging of Pleural and Peritoneal Disease

1.Gill, RR, Gerbaudo, VH, Jacobson, FL, Trotman-Dickenson, B, Matsuoka, S, Hunsaker, A, et al. MR imaging of benign and malignant pleural disease. Magn Reson Imaging Clin N Am. 2008;16:319–39, x. Available from:
2.Benamore, RE, Warakaulle, DR, Traill, ZC. Imaging of pleural disease. Imaging. 2008;20(4):236–51.
3.Salahudeen, HM, Hoey, ETD, Robertson, RJ, Darby, MJ. CT appearances of pleural tumours. Clin Radiol. 2009;64(9):918–30.
4.Tirkes, T, Sandrasegaran, K, Patel, AA, Hollar, MA, Tejada, JG, Tann, M, et al. Peritoneal and retro peritoneal anatomy and its relevance for cross sectional imaging 1. RadioGraphics. 2012;32(2):437–52. Available from:
5.Jeffrey, RB. Imaging of the peritoneal cavity. Curr Opin Radiol. 1991;3(3):471–73. Available from:
6.Liang, C, Shuang, L, Wei, L, Bolduc, J-P, Deslauriers, J. Correlative anatomy of the pleura and pleural spaces. Thorac Surg Clin. 2011;21(2):177–82, viiviii. Available from:
7.Frola, C, Cantoni, S, Turtulici, I, Leoni, C, Loria, F, Gaeta, M, et al. Transudative vs exudative pleural effusions: differentiation using Gd-DTPA-enhanced MRI. Eur Radiol. 1997;7:860–64.
9.Yalcin, NG, Choong, CKC, Eizenberg, N. Anatomy and pathophysiology of the pleura and pleural space. Thorac Surg Clin. 2013;23(1):110. Available from:
10.Light, RW. Pleural diseases. Disease-a-Month. 1992;266331.
11.Jones, PW, Moyers, JP, Rogers, JT, Rodriguez, RM, Lee, YCG, Light, RW. Ultrasound-guided thoracentesis: is it a safer method? Chest. 2003;123(2):418–23. Available from:\n papers3://publication/uuid/2F7D1E6D-5288–492C-9DC7-FDD3EFB95D39
12.McLoud, TC, Flower, CDR. Imaging the pleura: sonography, CT, and MR imaging. AJR Am J Roentgenol. 1991;156:1145–53.
13.Barnes, TW, Morgenthaler, TI, Olson, EJ, Hesley, GK, Decker, PA, Ryu, JH. Sonographically guided thoracentesis and rate of pneumothorax. J Clin Ultrasound. 2005;33:442–46.
14.Kataoka, H, Takada, S. The role of thoracic ultrasonography for evaluation of patients with decompensated chronic heart failure. J Am Coll Cardiol. 2000;35(6):1638–46.
15.Koenig, SJ, Narasimhan, M, Mayo, PH. Thoracic ultrasonography for the pulmonary specialist. Chest. 2011;140(5):1332–41.
16.Agmy, GM, Wafy, S, Hussein, A. Transthoracic Doppler chest ultrasonography: the current situation. Chest. 2010;138(4):818A. Available from:–9d92-f0b4ba559563\n
17.Yilmaz, U, Polat, G, Sahin, N, Soy, O, Gülay, U. CT in differential diagnosis of benign and malignant pleural disease. Monaldi Arch Chest Dis. 2005;63(1):1722. Available from:
18.Baysal, T, Bulut, T, Gökirmak, M, Kalkan, S, Dusak, A, Dogan, M. Diffusion-weighted MR imaging of pleural fluid: differentiation of transudative vs exudative pleural effusions. European Radiology. 2004;14(5):890–96. Available from:
19.Heelan, RT, Rusch, VW, Begg, CB, Panicek, DM, Caravelli, JF, Eisen, C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol. 1999;172:1039–47.
20.Gupta, NC, Rogers, JS, Graeber, GM, Gregory, JL, Waheed, U, Mullet, D, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest. 2002;122:1918–24.
21.Pannu, HK, Bristow, RE, Frederick, J. Multidetector CT of peritoneal carcinomatosis from ovarian cancer. Radiographics. 2003;23(3):687701.
22.Gore, RM, Newmark, GM, Thakrar, KH, Mehta, UK, Berlin, JW. Pathways of abdominal tumour spread: the role of the subperitoneal space. Cancer Imaging. 2009;9:112–20. Available from:
23.Lynch, KC, Oliveira, CR, Matheson, JS, Mitchell, MA, O’Brien, RT. Detection of pneumothorax and pleural effusion with horizontal beam radiography. Vet Radiol Ultrasound. 2012;53(1):3843.
24.Wilkerson, RG, Stone, MB. Sensitivity of bedside ultrasound and supine anteroposterior chest radiographs for the identification of pneumothorax after blunt trauma. Acad Emerg Med. 2010;17:1117.
25.Diacon, AH, Theron, J, Bolliger, CT. Transthoracic ultrasound for the pulmonologist. Curr Opin Pulm Med. 2005;11(4):307–12.
26.Ko, JM, Park, HJ, Kim, CH. Pulmonary changes of pleural tuberculosis: up-to-date CT imaging. Chest. 2014;138(4):1604–11. Available from:
27.Baumann, MH, Nolan, R, Petrini, M, Lee, YCG, Light, RW, Schneider, E. Pleural tuberculosis in the United States: incidence and drug resistance. Chest. 2007;131:1125–32.
28.Mimidis, K, Ritis, K, Kartalis, G. Peritoneal tuberculosis. Ann Gastroenterol. 2005;18(3):325–29.
29.Ti, JP, Al-Aradi, A, Conlon, PJ, Lee, MJ, Morrin, MM. Imaging features of encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. AJR Am J Roentgenol. 2010;195(1):W5054.
30.Hillerdal, G. Mesothelioma: cases associated with non-occupational and low dose exposures. Occup Environ Med. 1999;56:505–13.
31.Fletcher, AC, Engholm, G, Englund, A. The risk of lung cancer from asbestos among Swedish construction workers: self-reported exposure and a job exposure matrix compared. Int J Epidemiol. 1993;22(Suppl 2):S2935. Available from:
32.Fortier, M, Mayo, JR, Swensen, SJ, Munk, PL, Vellet, DA, Müller, NL. MR imaging of chest wall lesions. Radiographics. 1994;14(3):597606.
33.Inaoka, T, Takahashi, K, Miyokawa, N, Ohsaki, Y, Aburano, T. Solitary fibrous tumor of the pleura: apparent diffusion coefficient (ADC) value and ADC map to predict malignant transformation. J Magn Reson Imaging. 2007;26(1):155–58. Available from:
34.Tateishi, U, Gladish, GW, Kusumoto, M, Hasegawa, T, Yokoyama, R, Tsuchiya, R, et al. Chest wall tumors: radiologic findings and pathologic correlation. Radiographics. 2003;23(6):1477–90. Available from:\n\n
35.Jeung, MY, Gangi, A, Gasser, B, Vasilescu, C, Massard, G, Wihlm, JM, et al. Imaging of chest wall disorders. Radiographics. 1999;19(3):617–37.
36.Lee, TJ, Collins, J. MR imaging evaluation of disorders of the chest wall. Magn Reson Imag Clin N Am. 2008;16(2):355–79.
37.Yang, H, Testa, JR, Carbone, M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008;9(2–3):147–57.
38.Weill, H, Hughes, JM, Churg, A. Changing trends in US mesothelioma incidence. Occup Environ Med. 2005;62:270.
39.Price, B, Ware, A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol. 2004;159(2):107–12. Available from:\n
40.Price, B, Ware, A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39(7):576–88.
41.Peto, J, Decarli, A, La Vecchia, C, Levi, F, Negri, E. The European mesothelioma epidemic. Br J Cancer. 1999;79(3–4):666–72.
42.Tarrés, J, Albertí, C, Martínez-Artés, X, Abós-Herràndiz, R, Rosell-Murphy, M, García-Allas, I, et al. Pleural mesothelioma in relation to meteorological conditions and residential distance from an industrial source of asbestos. Occup Environ Med. 2013;70(8):588–90. Available from:
43.Awad, AHA. Environmental study in subway metro stations in Cairo, Egypt. J Occup Health. 2002;44:112–18.
44.Gill, RR. Imaging of mesothelioma. Recent Results Cancer Res. 2011;189:2743.
45.Bueno, R, Reblando, J, Glickman, J, Jaklitsch, MT, Lukanich, JM, Sugarbaker, DJ. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg. 2004;78:1774–76.
46.Yildirim, H, Metintas, M, Entok, E, Ak, G, Ak, I, Dundar, E, et al. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol. 2009;4(12):1480–84.
47.Wang, ZJ, Reddy, GP, Gotway, MB, Higgins, CB, Jablons, DM, Ramaswamy, M, et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics. 2004;24:105–19. Available from:
48.Kawashima, A, Libshitz, HI. Malignant pleural mesothelioma: CT manifestations in 50 cases. AJR Am J Roentgenol. 1990;155:965–69.
49.Erasmus, JJ, Truong, MT, Smythe, WR, Munden, RF, Marom, EM, Rice, DC, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg. 2005;129(6):1364–70. Available from:
50.Gill, RR, Gerbaudo, VH, Sugarbaker, DJ, Hatabu, H. Current trends in radiologic management of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21:111–20.
51.Abdel, Rahman ARM, Gaafar, RM, Baki, HA, El Hosieny, HM, Aboulkasem, F, Farahat, EG, et al. Prevalence and pattern of lymph node metastasis in malignant pleural mesothelioma. Ann Thorac Surg. 2008;86(2):391–95. Available from:
52.Antman, KH, Corson, JM. Benign and malignant pleural mesothelioma. Clin Chest Med. 1985;6:127–40.
53.Sugarbaker, DJ, Mentzer, SJ, DeCamp, M, Lynch, TJ, Strauss, GM. Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. Chest. 1993;103(4 Suppl):377S81S. Available from:
54.Pilling, JE, Stewart, DJ, Martin-Ucar, AE, Muller, S, Byrne, KJO, Waller, DA. The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. Eur J Cardiothor Surg. 2004;25:497501.
55.Patz, EF, Rusch, VW, Heelan, R. The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging. AJR Am J Roentgenol. 1996;166:323–27.
56.Gill, RR, Richards, WG, Yeap, BY, Matsuoka, S, Wolf, AS, Gerbaudo, VH, et al. Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume. AJR Am J Roentgenol. 2012;198(2):359–63. Available from:
57.Flores, RM, Pass, HI, Seshan, VE, Dycoco, J, Zakowski, M, Carbone, M, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620–6, 626.e1–3. Available from:
58.Rusch, VW, Giroux, D, Kennedy, C, Ruffini, E, Cangir, AK, Rice, D, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7(11):1631–39. Available from:
59.Aziz, T, Jilaihawi, A, Prakash, D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg. 2002;22:298305. Available from:
60.Richards, WG, Godleski, JJ, Yeap, BY, Corson, JM. Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. Cancer. 2010;1510–17.
61.Van Meerbeeck, JP, Scherpereel, A, Surmont, VF, Baas, P. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol. 2011;78(2):92111. Available from: = 1040–8428&isbn = &volume = 78&issue = 2&spage = 92&pages = 92–111&date = 2011&title = Critical+Reviews+in+Oncology-Hematology&atitle = Malignant+pleur
62.Flores, RM, Akhurst, T, Gonen, M, Zakowski, M, Dycoco, J, Larson, SM, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2006;132(4):763–68.
63.Nakas, A, Black, E, Entwisle, J, Muller, S, Waller, DA. Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage? Eur J Cardio-Thoracic Surg. 2010;37(6):1457–63. Available from:
64.Rusch, VW, Giroux, D. Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Ann Cardiothorac Surg. 2012;1(4):438–48. Available from:
65.Sugarbaker, DJ, Strauss, GM, Lynch, TJ, Richards, W, Mentzer, SJ, Lee, TH, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol. 1172;11(6):1172–78. Available from:
66.Rusch, V, Baldini, EH, Bueno, R, De Perrot, M, Flores, R, Hasegawa, S, et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, Mass. J Thorac Cardiovasc Surg. 2013;145(4):909–10. Available from:
67.Schouwink, JH, Kool, LS, Rutgers, EJ, Zoetmulder, FAN, van Zandwijk, N, v d Vijver, MJ, et al. The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. Ann Thorac Surg. 2003;75(6):1715–18; discussion 1718–19. Available from:
68.Abdel, Razek AAK, Soliman, NY, Elkhamary, S, Alsharaway, MK, Tawfik, A. Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol. 2006;16(7):1468–77.
69.Kent, M, Rice, D, Flores, R. Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol. 2008;9(2–3):158–70. Available from:
70.Jänne, PA, Baldini, EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin. 2004;14:567–73.
71.Baldini, EH, Recht, A, Strauss, GM, DeCamp, MM, Swanson, SJ, Liptay, MJ, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 1997;63(2):334–38. Available from:
72.Byrne, MJ. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15(2):257–60. Available from:
73.Armato, SG. Computerized analysis of mesothelioma on CT scans. Lung Cancer. 2005;49(Suppl 1):S4144.
74.Armato, SG, Ogarek, JL, Starkey, A, Vogelzang, NJ, Kindler, HL, Kocherginsky, M, et al. Variability in mesothelioma tumor response classification. AJR Am J Roentgenol. 2006;186(4):1000–06.
75.Kaira, K, Serizawa, M, Koh, Y, Takahashi, T, Hanaoka, H, Oriuchi, N, et al. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer. 2012;48:1244–54.
76.Nowak, AK, Francis, RJ, Phillips, MJ, Millward, MJ, Van Der Schaaf, AA, Boucek, J, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res. 2010;16(8):2409–17.
77.Pickhardt, PJ, Bhalla, S. Primary neoplasms of peritoneal and sub-peritoneal origin: CT findings. Radiographics. 2005;25(4):983–95.
78.Kebapci, M, Yalcin, OT, Dundar, E, Ozalp, SS, Kaya, T. Computed tomography findings of primary serous papillary carcinoma of the peritoneum in women. Eur J Gynaecol Oncol. 2003;24(6):552–56. Available from:\n–2936&isbn=&volume=24&issue=6&spage=552&pages=552–556&date=2003&title=Euro
79.Bonomo, L, Feragalli, B, Sacco, R, Merlino, B, Storto, ML. Malignant pleural disease. Eur J Radiol. 2000;34:98118.
80.Low, RN, Sigeti, JS. MR imaging of peritoneal disease: comparison of contrast-enhanced fast multiplanar spoiled gradient-recalled and spin-echo imaging. AJR Am J Roentgenol. 1994;163(5):1131–40. Available from:
81.Heelan, RT, Demas, BE, Caravelli, JF, Martini, N, Bains, MS, McCormack, PM, et al. Superior sulcus tumors: CT and MR imaging. Radiology. 1989;170:637–41.
82.Coolen, J, De Keyzer, F, Nafteux, P, De Wever, W, Dooms, C, Vansteenkiste, J, et al. Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging – initial experience. Radiology. 2012;263(3):884–92.
83.Healy, JC. Detection of peritoneal metastases. Cancer Imaging. 2001;1(2):412. Available from:
84.Patel, CM, Sahdev, A, Reznek, RH. CT, MRI and PET imaging in peritoneal malignancy. Cancer Imaging. 2011;11(1):123–39.
85.Oei, TN, Jagannathan, JP, Ramaiya, N, Ros, PR. Peritoneal sarcomatosis versus peritoneal carcinomatosis: imaging findings at MDCT. AJR Am J Roentgenol. 2010;195(3):229–35.
86.Cabral, FC, Krajewski, KM, Kim, KW, Ramaiya, NH, Jagannathan, JP. Peritoneal lymphomatosis: CT and PET/CT findings and how to differentiate between carcinomatosis and sarcomatosis. Cancer Imaging. 2013;13:162–70. Available from:
87.Diop, D, Fontarensky, M, Montoriol, P, Da Ines, D. CT imaging of peritoneal carcinomatosis and its mimics. Diagn Interv Imaging. 2014;95(9):861–72. Available from:
88.Kwee, TC, Takahara, T, Ochiai, R, Nievelstein, R a J, Luijten, PR. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol. 2008;18(9):1937–52.
89.Sala, E, Priest, AN, Kataoka, M, Graves, MJ, McLean, MA, Joubert, I, et al. Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla: technical development. Eur Radiol. 2010;20(2):491–96. Available from:
90.Bammer, R, Holdsworth, SJ, Veldhuis, WB, Skare, ST. New methods in diffusion-weighted and diffusion tensor imaging. Magn Reson Imaging Clin N Am. 2009;17(2):175204. Available from:
91.Armato, SG, Labby, ZE, Coolen, J, Klabatsa, A, Feigen, M, Persigehl, T, et al. Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group. Lung Cancer. 2013;82(2):190–96.
92.Gill, RR, Umeoka, S, Mamata, H, Tilleman, TR, Stanwell, P, Woodhams, R, et al. Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes. AJR Am J Roentgenol. 2010;195(2):W125–30. Available from:
93.Giesel, FL, Choyke, PL, Mehndiratta, A, Zechmann, CM, von Tengg-Kobligk, H, Kayser, K, et al. Pharmacokinetic analysis of malignant pleural mesothelioma – initial results of tumor microcirculation and its correlation to microvessel density (CD-34). Acad Radiol. 2008;15(5):563–70. Available from:
94.Jeswani, T, Padhani, AR. Imaging tumour angiogenesis. Cancer Imaging. 2005;5:131–38. Available from:
95.Goel, HL, Mercurio, AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871–82. Available from:
96.Giesel, FL, Bischoff, H, Von Tengg-Kobligk, H, Weber, MA, Zechmann, CM, Kauczor, HU, et al. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome. Chest. 2006;129(6):1570–76.
97.Priest, A, Sala, E, Graves, M, Joubert, I, McLean, M, Griffin, N, et al. ADC and perfusion signal fraction measurements: feasibility in ovarian cancer at 3 Tesla. Proceedings 16th Scientific Meeting, International Society for Magnetic Resonance in Medicine. 2008. p. 3846. Available from: /MyPathway2008/3846
98.Sala, E, Kataoka, MY, Priest, AN, Gill, AB, McLean, MA, Joubert, I, et al. Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. Radiology. 2012;263(1):149–59.
99.Lemke, A-J, Brinkmann, MJ, Schott, T, Niehues, SM, Settmacher, U, Neuhaus, P, et al. Living donor right liver lobes: preoperative CT volumetric measurement for calculation of intraoperative weight and volume. Radiology. 2006;240(3):736–42.
100.Dello, SAWG, Stoot, JHMB, van Stiphout, RSA, Bloemen, JG, Wigmore, SJ, Dejong, CHC, et al. Prospective volumetric assessment of the liver on a personal computer by nonradiologists prior to partial hepatectomy. World J Surg. 2011;35(2):386–92. Available from:
101.Frauenfelder, T, Tutic, M, Weder, W, Götti, RP, Stahel, RA, Seifert, B, et al. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Eur Respir J. 2011;38(1):162–68.
102.Yoshida, Y, Kurokawa, T, Sawamura, Y, Shinagawa, A, Okazawa, H, Fujibayashi, Y, et al. The positron emission tomography with F18 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer. Gynecol Oncol. 2007;104(3):764–66. Available from: